{"success":true,"data":{"pressRelease":{"id":"126293","rtpr_id":"nACS5vkpna","ticker":"TNON","exchange":"NASDAQ","all_tickers":["TNON"],"title":"Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement","author":"ACCESSWIRE","published_at":"2026-08-24T17:00:02.138Z","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / August 24,\n2026 / Tenon Medical, Inc. (https://pr.report/pgdw) (NASDAQ:TNON) (\"Tenon\" or\nthe \"Company\"), a medical device company dedicated to transforming care for\npatients with certain sacro-pelvic disorders, today announced that it has\nreceived notice from The Nasdaq Stock Market LLC (\"Nasdaq\") confirming that\nthe Company has regained compliance with the minimum bid price requirement\nunder Nasdaq Listing Rule 5550(a)(2) (the \"Bid Price Rule\").\n\nOn February 25, 2026, the Company received a letter from the Listing\nQualifications staff of Nasdaq (the \"Staff\") notifying it that, for the prior\n30 consecutive business days, the closing bid price of the Company's common\nstock had been below the $1.00 per share minimum required under the Bid Price\nRule.\n\nFollowing the Company's previously announced 1-for-35 reverse stock split,\neffective August 10, 2026, the closing bid price of the Company's common stock\nwas $1.00 per share or greater for each of the 10 consecutive business days\nfrom August 10, 2026 through August 21, 2026. On August 24, 2026, the Staff\nnotified the Company in writing that the Company has regained compliance with\nthe Bid Price Rule and that this matter is now closed.\n\nThe Company's common stock continues to trade on the Nasdaq Capital Market\nunder the symbol \"TNON.\"\n\nAbout Tenon Medical, Inc.\n\n(https://app.accessnewswire.com/imagelibrary/5f61906c-6682-4723-a8e2-c004870af9be/image.jpeg)\n\nTenon Medical, Inc. is a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran(™) SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+(®) SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAIL(™), and SImmetry+ are also trademarks of Tenon\nMedical, Inc.\n\nSafe Harbor\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking\nstatements often contain words such as \"intends,\" \"estimates,\" \"anticipates,\"\n\"hopes,\" \"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\"\n\"will,\" \"would,\" \"target,\" and similar expressions and the negative versions\nthereof. These forward-looking statements include, but are not limited to,\nstatements regarding the Company's ability to maintain compliance with Nasdaq\nlisting requirements and the continued listing of the Company's common stock\non the Nasdaq Capital Market. Such statements are based on Tenon's experience\nand perception of current conditions, trends, expected future developments and\nother factors it believes are appropriate under the circumstances, and speak\nonly as of the date made. Forward-looking statements are inherently uncertain\nand actual results may differ materially from assumptions, estimates or\nexpectations reflected or contained in the forward-looking statements as a\nresult of various factors. For details on the uncertainties that may cause\nTenon's actual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov, particularly the information contained in the section entitled\n\"Risk Factors.\" We undertake no obligation to publicly update or revise any\nforward-looking statements to reflect new information or future events or\notherwise unless required by law.\n\nIR Contact:\n\nShannon Devine\n203-741-8811\nMZ North America\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-regains-compliance-with-nasdaq-minimum-bid-price-requir-1211202)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS5vkpna","title":"Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement","author":"ACCESSWIRE","ticker":"TNON","created":"2026-08-24T17:00:02.138Z","tickers":["TNON"],"exchange":"NASDAQ","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / August 24,\n2026 / Tenon Medical, Inc. (https://pr.report/pgdw) (NASDAQ:TNON) (\"Tenon\" or\nthe \"Company\"), a medical device company dedicated to transforming care for\npatients with certain sacro-pelvic disorders, today announced that it has\nreceived notice from The Nasdaq Stock Market LLC (\"Nasdaq\") confirming that\nthe Company has regained compliance with the minimum bid price requirement\nunder Nasdaq Listing Rule 5550(a)(2) (the \"Bid Price Rule\").\n\nOn February 25, 2026, the Company received a letter from the Listing\nQualifications staff of Nasdaq (the \"Staff\") notifying it that, for the prior\n30 consecutive business days, the closing bid price of the Company's common\nstock had been below the $1.00 per share minimum required under the Bid Price\nRule.\n\nFollowing the Company's previously announced 1-for-35 reverse stock split,\neffective August 10, 2026, the closing bid price of the Company's common stock\nwas $1.00 per share or greater for each of the 10 consecutive business days\nfrom August 10, 2026 through August 21, 2026. On August 24, 2026, the Staff\nnotified the Company in writing that the Company has regained compliance with\nthe Bid Price Rule and that this matter is now closed.\n\nThe Company's common stock continues to trade on the Nasdaq Capital Market\nunder the symbol \"TNON.\"\n\nAbout Tenon Medical, Inc.\n\n(https://app.accessnewswire.com/imagelibrary/5f61906c-6682-4723-a8e2-c004870af9be/image.jpeg)\n\nTenon Medical, Inc. is a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran(™) SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+(®) SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAIL(™), and SImmetry+ are also trademarks of Tenon\nMedical, Inc.\n\nSafe Harbor\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking\nstatements often contain words such as \"intends,\" \"estimates,\" \"anticipates,\"\n\"hopes,\" \"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\"\n\"will,\" \"would,\" \"target,\" and similar expressions and the negative versions\nthereof. These forward-looking statements include, but are not limited to,\nstatements regarding the Company's ability to maintain compliance with Nasdaq\nlisting requirements and the continued listing of the Company's common stock\non the Nasdaq Capital Market. Such statements are based on Tenon's experience\nand perception of current conditions, trends, expected future developments and\nother factors it believes are appropriate under the circumstances, and speak\nonly as of the date made. Forward-looking statements are inherently uncertain\nand actual results may differ materially from assumptions, estimates or\nexpectations reflected or contained in the forward-looking statements as a\nresult of various factors. For details on the uncertainties that may cause\nTenon's actual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov, particularly the information contained in the section entitled\n\"Risk Factors.\" We undertake no obligation to publicly update or revise any\nforward-looking statements to reflect new information or future events or\notherwise unless required by law.\n\nIR Contact:\n\nShannon Devine\n203-741-8811\nMZ North America\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-regains-compliance-with-nasdaq-minimum-bid-price-requir-1211202)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-08-24T17:00:02.216737529Z","server_sent_at_ms":1787590802216},"received_at":"2026-08-24T17:00:02.266Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medical-regains-compliance-with-nasdaq-minimum-bid-price-requir-1211202"},"analysis":{"id":"115236","press_release_id":"126293","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":["Reverse split ratio of 1-for-35 required to regain compliance","Prior non-compliance due to bid price falling below $1.00 threshold"],"eventType":"reverse_split","narrative":"Tenon Medical regained compliance with Nasdaq's $1.00 minimum bid price requirement after maintaining a closing bid price of at least $1.00 for 10 consecutive business days.\n\nThe compliance was achieved following the effectiveness of a previously announced 1-for-35 reverse stock split on August 10, 2026.\n\nNasdaq has notified the company that the matter is now closed and its common stock will continue to trade on the Nasdaq Capital Market.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Tenon Medical retains Nasdaq listing after massive 1-for-35 reverse split."},"keyFigures":{"customDimensions":{"reverse_split_ratio":"1-for-35"}},"quotedText":"","namedEntities":{"people":[{"name":"Shannon Devine","role":"IR Contact"}],"products":["The Catamaran SI Joint Fusion System","SImmetry+ SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"SiVantage, Inc.","relationship":"acquired asset"},{"name":"SIMPL Medical, LLC","relationship":"acquired asset"}],"dollarAmounts":[{"amount":"$1.00","context":"Nasdaq minimum bid price requirement"}]},"materialImpact":{"score":4,"reasoning":"The company executed a 1-for-35 reverse stock split to regain compliance, a high ratio indicating significant prior share price erosion and distress."},"tickerRelevance":{"others":[],"primary":"TNON"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["regulatory"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"extreme_reverse_split","sectorWeight":"health_care"}},"event_type":"reverse_split","event_type_secondary":["regulatory"],"sentiment":"bearish","material_impact_score":4,"narrative":"Tenon Medical regained compliance with Nasdaq's $1.00 minimum bid price requirement after maintaining a closing bid price of at least $1.00 for 10 consecutive business days.\n\nThe compliance was achieved following the effectiveness of a previously announced 1-for-35 reverse stock split on August 10, 2026.\n\nNasdaq has notified the company that the matter is now closed and its common stock will continue to trade on the Nasdaq Capital Market.","key_figures":{"customDimensions":{"reverse_split_ratio":"1-for-35"}},"named_entities":{"people":[{"name":"Shannon Devine","role":"IR Contact"}],"products":["The Catamaran SI Joint Fusion System","SImmetry+ SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"SiVantage, Inc.","relationship":"acquired asset"},{"name":"SIMPL Medical, LLC","relationship":"acquired asset"}],"dollarAmounts":[{"amount":"$1.00","context":"Nasdaq minimum bid price requirement"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-24T17:03:26.832Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"extreme_reverse_split","sectorWeight":"health_care"}},"durationMs":138856,"modelName":"glm-4.7"}}